Good day for Cara


Shares of thinly-traded recent IPO Cara Therapeutics (CARA +18%) pop on a 2x surge in volume, albeit only ~110K shares thus far in today's session. The company is developing products to treat diseases associated with pain and inflammation. Its lead product is CR845, a peripheral kappa opioid receptor agonist. The company has completed three Phase 2 trials evaluating CR845 in acute post-operative pain. Its value proposition is opioid-like pain relief without the CNS-mediated side effects such as potential dependence, respiratory suppression and bowel suppression.

Two days ago, Cara announced that the first patients were dosed in a Phase 1a/1b study assessing CR845 as a treatment for acute and chronic pain.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs